Biosimilars – Commercial Best Practices In The Age Of Sustainability
Key Rules Of The Road’ For Biosimilar Developers
Executive Summary
If there is one fact that even the most casual observer of the pharma industry is aware of, it is that biologics are the leading growth engine of global medicines spending. According to IQVIA, revenues from biologics increased by 70% during 2011-2016 to reach $232bn, accounting for roughly 20-22% of total pharmaceutical spending.